Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2019
At a glance
- Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms FCR
- 11 Apr 2019 Planned End Date changed from 1 Aug 2018 to 1 Oct 2019.
- 11 Apr 2019 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2019.
- 31 Aug 2018 Biomarkers information updated